Literature DB >> 12149160

Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia?

Mohamed A Ghafar1, Peter J Puchner, Aristotelis G Anastasiadis, Mark A Cabelin, Ralph Buttyan.   

Abstract

Benign prostatic hyperplasia (BPH) is a disease condition characterized by abnormal prostate growth in conjunction with distinct lower urinary tract symptoms. This paper considers the extent to which the prostatic vascular system contributes to normal prostate growth control as well as whether abnormal blood flow patterns in the aging prostate gland might lead to hypoxia-stimulated prostate growth. This relationship is posited from accumulated research that suggests the prostatic vascular system is a primary androgen action target and other research demonstrating the diverse effects of hypoxia in eliciting cell death or cell growth responses. This hypothesis is further supported by the coincidental clinical finding that the presence of cardiovascular disease conditions are among the general risk factors for the development of BPH, and that cardiovascular-active drugs can be used for the treatment of BPH symptoms. This hypothesis has major implications for our understanding of the etiology of BPH, as well as for the development of new and better treatments for this extremely common condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149160     DOI: 10.1007/s11934-002-0051-2

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  20 in total

Review 1.  Worldwide experience with alfuzosin and tamsulosin.

Authors:  M C Michel; M T Flannery; P Narayan
Journal:  Urology       Date:  2001-10       Impact factor: 2.649

2.  Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up.

Authors:  M I Miller; P J Puchner
Journal:  Urology       Date:  1998-02       Impact factor: 2.649

3.  Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men.

Authors:  K M Weisman; G E Larijani; M R Goldstein; M E Goldberg
Journal:  Pharmacotherapy       Date:  2000-04       Impact factor: 4.705

4.  Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer.

Authors:  D Cvetkovic; B Movsas; A P Dicker; A L Hanlon; R E Greenberg; J D Chapman; G E Hanks; J V Tricoli
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

5.  Early effects of castration on the vascular system of the rat ventral prostate gland.

Authors:  A Shabisgh; N Tanji; V D'Agati; M Burchardt; M Rubin; E T Goluboff; D Heitjan; A Kiss; R Buttyan
Journal:  Endocrinology       Date:  1999-04       Impact factor: 4.736

6.  Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction.

Authors:  R Buttyan; M W Chen; R M Levin
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

7.  Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity.

Authors:  O R Hayek; A Shabsigh; S A Kaplan; A J Kiss; M W Chen; T Burchardt; M Burchardt; C A Olsson; R Buttyan
Journal:  J Urol       Date:  1999-10       Impact factor: 7.450

8.  Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats.

Authors:  I Franck-Lissbrant; S Häggström; J E Damber; A Bergh
Journal:  Endocrinology       Date:  1998-02       Impact factor: 4.736

9.  Androgen receptor localization in different cell types of the adult rat prostate.

Authors:  G S Prins; L Birch; G L Greene
Journal:  Endocrinology       Date:  1991-12       Impact factor: 4.736

10.  Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival.

Authors:  A Shabsigh; D T Chang; D F Heitjan; A Kiss; C A Olsson; P J Puchner; R Buttyan
Journal:  Prostate       Date:  1998-08-01       Impact factor: 4.104

View more
  8 in total

Review 1.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

2.  Mechanisms involved in the nitric oxide-induced vasorelaxation in porcine prostatic small arteries.

Authors:  Vítor S Fernandes; Ana Martínez-Sáenz; Paz Recio; Ana S F Ribeiro; Ana Sánchez; María Pilar Martínez; Ana Cristina Martínez; Albino García-Sacristán; Luis M Orensanz; Dolores Prieto; Medardo Hernández
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-12       Impact factor: 3.000

Review 3.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

4.  Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia.

Authors:  A P Berger; M Deibl; E J Halpern; M Lechleitner; J Bektic; W Horninger; G Fritsche; H Steiner; A Pelzer; G Bartsch; F Frauscher
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

5.  Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH.

Authors:  Motoaki Saito; Panagiota Tsounapi; Ryo Oikawa; Shogo Shimizu; Masashi Honda; Takehiro Sejima; Yukako Kinoshita; Shuhei Tomita
Journal:  Sci Rep       Date:  2014-01-22       Impact factor: 4.379

6.  Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy.

Authors:  Daniel S R Angrimani; Maria Claudia P Francischini; Maíra M Brito; Camila I Vannucchi
Journal:  PLoS One       Date:  2020-06-25       Impact factor: 3.240

7.  Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH).

Authors:  Miriam Saponaro; Isabella Giacomini; Giulia Morandin; Veronica Cocetta; Eugenio Ragazzi; Genny Orso; Ilaria Carnevali; Massimiliano Berretta; Mariangela Mancini; Francesco Pagano; Monica Montopoli
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

8.  Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model.

Authors:  Raffaella Leoci; Giulio Aiudi; Fabio Silvestre; Elaine Lissner; Giovanni Michele Lacalandra
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.